Associations between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy, Tirzepetide vs. Dulaglutide or Semaglutide on major cardiovascular events in T2D, and more!

Welcome to the latest episode (May 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.

This month, they discuss:

Marston NA, Bohula EA, Bhatia AK, et al. "Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial." JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277
Lee YJ, Lee SJ, Kim JW, et al. "Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease." N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283
Nissen SE, Wolski K, D'Alessio D, et al. "Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial." JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767
Moura FA, et al. "Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis." Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238
Ostrominski JW, Ortega-Montiel J, et al. "Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations." Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063
Nicole Napoli, "Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events." The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events

For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(100)

Anna Kahkoska & Joshua Niznik on Patient Portal Messages and Older Adults with T2D, Esben Thyssen Vestergaard on Clinic for Athletes with T1D, and more!

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE...

10 Juni 38min

Food coloring additives & T2D, automated insulin delivery systems in T2D, and more!

Welcome to the latest episode (June 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic ...

2 Juni 38min

Special Edition: Obesity Processes and PATHWEIGH for Obesity Care

In this special edition of Diabetes Core Update, Neil Skolnik discusses PATHWEIGH, a novel obesity care process for primary care clinicians which has demonstrated a decrease in population weight gain....

29 Maj 30min

Special Edition: Obesity—The Changing Landscape

In the first episode of this series on Obesity, our host is joined by Dr. Mikhail Kosiborod to discuss the evolving science and cardiometabolic diseases associated with obesity. This special episode i...

26 Maj 33min

Special Edition: What's Next—Cortisol, Metabolism & Future Innovation, Part 4

Is hypercortisolism the hidden culprit in a significant proportion of both difficult-to-treat diabetes and resistant hypertension? In part 4 of our special series, Dr. Neil Skolnik speaks with John Bu...

19 Maj 27min

Special Edition: What's Next—Cardiovascular Risk in CKD—The Overlooked Burden

We have only recently become aware of the close relationship between the heart and the kidneys. In today's discussion, Dr. Neil Skolnik speaks with Dr. Josephine Harrington to gain insight into these ...

12 Maj 30min

Special Edition: What's Next—Once-Weekly Insulin

In the early 2000s, long-acting, once-daily insulin was approved, completely changing the experience of using insulin for people with diabetes. But science doesn't stand still. Now the FDA has approve...

5 Maj 20min